Spotlight on: ASCO 2025

From the congress floor: ASCO 2025 in review

May 30 - June 3, 2025 | McCormick Place, Chicago, IL & Online

2025 ASCO Annual Meeting

ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content captured live from the congress floor in Chicago.

Over the coming weeks, we’ll be rolling out analysis and reaction to the biggest talking points from this year’s event, including AI, innovative biomarkers, new treatment fields, and much more.

Whether you joined us onsite or are catching up remotely, stay tuned for pharmaphorum’s continued reporting from one of the most impactful events on the oncology calendar – featuring voices from across the field and reflections on what the latest findings mean for the future of cancer care.

Content Highlights

🎥 ASCO 2025 insights: EVERSANA experts on AI, biomarkers, and the future of oncology

🎥Disrupting cancer cell division: How tumour treating fields are changing oncology

🎥Breaking barriers to CAR T-cell therapy: The vision for expanding patient access

၊၊||၊ Live from ASCO 2025: Boehringer Ingelheim on unmet needs and oncology innovation

🎥Regeneron at ASCO 25: Advancing multiple myeloma treatment

Nicole Raleigh

Reported by Nicole Raleigh

Nicole Raleigh is pharmaphorum’s web editor. Transitioning to the healthcare sector in the last few years, she is an experienced media and communications professional who has worked in print and digital for over 20 years.

Highlights from the past ASCO conferences

Heard on the pipeline: ASCO 2024

Every year, the American Society of Clinical Oncology (ASCO) annual meeting brings together a worldwide community of innovators dedicated to advancing the frontiers of cancer research.

Amidst a wealth of knowledge and experience, pharmaphorum editor-in-chief, Jonah Comstock, was presented with a profound opportunity on the ASCO floor: the passing of the torch to the next generation of oncology experts.

 

READ MORE
Oncology
Video interview with Matteo Levisetti

ASCO 2024 - Matteo Levisetti

ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.

Oncology
ASCO 2024 - Steve Devine interview with Jonah Comstock

ASCO 2024 - Steve Devine

While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.

Oncology
ASCO 2024 - Chris Haqq interview with Jonah Comstock

ASCO 2024 - Chris Haqq

ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p

Oncology
Michael Petroutsas at ASCO 2024

ASCO 2024 - Michael Petroutsas

Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the si

Oncology
Andree Amelsberg at ASCO 2024 and Jonah Comstock

ASCO 2024 - Andree Amelsberg

At ASCO 2024 last month, editor-in-chief Jonah Comstock caught up with Dr Andree Amelsberg, SVP of global and US medical affairs at Eisai, to chat about what the company was sharing at the

Oncology
Jonah Comstock and Thanos Zomas at ASCO 2024

ASCO 2024 – Thanos Zomas

Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid

Oncology
Scot Ebbinghaus at ASCO 2024

ASCO 2024 - Scot Ebbinghaus

Merck & Co (MSD outside the United States) celebrated the tenth anniversary of the first Keytruda approval at ASCO this year, but the company isn’t resting on its laurels.

Oncology
Henar Hevia and Carolyn Sousa at ASCO 2024

ASCO 2024 - Henar Hevia and Carolyn Sousa

The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers.

Oncology
Paul Burton interview with Jonah Comstock

ASCO 2024 - Paul Burton

For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer.

Oncology
ASCO24

Four takeaways from ASCO24

Last weekend, I travelled to Chicago for the annual conference of the American Society of Clinical Oncologists— the annual event where major breakthroughs in cancer care are announced.

R&D
Dr Suzanne Trudel at ASCO 2024

ASCO 2024 - Suzanne Trudel

Sometimes getting a new drug to market is a relatively straight line, but sometimes it’s a winding road.

Oncology
ASCO Mohit Manrao feature

ASCO 2024 - Mohit Manrao

Just about everyone seems to agree that the runaway success story of ASCO this year is AstraZeneca, with plenary sessions for the sixth year in a row and

About ASCO

The 2025 ASCO Annual Meeting programme will feature over 200 sessions complementing Dr Robin Zon's Presidential theme, Driving Knowledge to Action: Building a Better Future. View the official 2025 ASCO Annual Meeting programme announcement PDF for a message from the ASCO President, programme information, awards, and more.